host
suscept
respiratori
tract
infect
rti
depend
genet
acquir
risk
factor
repeat
bacteri
viral
rti
pneumonia
encapsul
microorgan
respiratori
tract
infect
relat
respiratori
syncyti
viru
influenza
even
develop
bronchiectasi
asthma
often
report
first
symptom
primari
immunodefici
way
neutropenia
wellknown
risk
factor
invas
aspergillosi
well
lymphopenia
pneumocysti
mycobacteri
infect
howev
last
decad
better
knowledg
immun
signal
network
introduct
next
gener
sequenc
increas
number
divers
known
inborn
error
immun
hand
use
monoclon
antibodi
target
cytokin
tumor
necrosi
factor
alpha
reveal
new
risk
group
infect
tuberculosi
use
biolog
respons
modifi
spread
almost
medic
specialti
includ
inflammatori
diseas
neoplasia
use
target
differ
signal
network
may
mirror
known
immun
defici
clinic
perspect
individu
contribut
genet
andor
target
treatment
immun
dysregul
difficult
assess
aim
articl
review
known
newli
describ
mechan
impair
immun
signal
predispos
rti
includ
new
insight
host
genet
impact
biolog
respons
modifi
summar
clinic
recommend
regard
vaccin
prophylact
treatment
order
prevent
infect
keyword
immunogenet
biolog
respons
modifi
respiratori
tract
infect
primari
immunodefici
inborn
error
epidemiolog
pathogenesi
respiratori
tract
infect
acut
chronic
respiratori
tract
infect
rti
one
frequent
caus
infect
antimicrobi
prescript
lead
caus
death
develop
countri
pneumonia
account
million
death
annual
children
year
age
million
peopl
die
tuberculosi
tb
children
age
year
account
total
death
higher
share
estim
case
suggest
poorer
access
diagnosi
treatment
billion
peopl
world
popul
estim
latent
tb
infect
control
latent
tb
stage
person
infect
mycobacterium
tuberculosi
play
import
role
diseas
control
sinc
dormant
bacilli
reservoir
potenti
tb
case
viral
acut
rti
estim
caus
acut
diseas
children
main
reason
hospit
worldwid
annual
preval
otherwis
healthi
child
infect
earli
recurr
lower
rti
link
higher
risk
develop
asthma
bronchiectasi
howev
bronchiectasi
secondari
recurr
sever
infect
alon
declin
increas
proport
patient
recogn
underli
condit
predispos
develop
improv
immun
program
wide
avail
antimicrobi
led
optim
devast
infecti
diseas
alway
without
forget
allevi
poverti
crucial
combin
genet
versatil
ecolog
opportun
microbi
world
appear
underestim
emerg
pathogen
legionella
avian
influenza
coronaviru
speci
describ
past
decad
ethnic
variat
incid
rti
also
report
suggest
genet
suscept
diseas
children
reach
year
age
contact
common
respiratori
virus
respiratori
syncyti
viru
rsv
develop
mild
diseas
other
develop
sever
bronchiol
influenza
virus
caus
mild
moder
respiratori
ill
peopl
develop
fatal
infect
virul
factor
encod
viral
gene
explain
season
geograph
differ
popul
level
unlik
account
interindividu
clinic
variabl
tb
outcom
depend
pathogen
extrins
element
well
host
factor
still
unclear
regard
bacteria
focus
speci
whose
normal
ecolog
nich
airway
therapeut
decis
daili
clinic
challeng
shift
commens
infect
shape
host
intrins
genet
extrins
factor
exampl
diet
exposur
cigarett
smoke
environment
pollut
bacteri
featur
also
contribut
interindividu
variabl
bacteria
develop
adapt
mechan
geneticphenotyp
level
order
surviv
hostil
environ
respiratori
tract
whether
pathogen
virul
gener
clinic
symptom
depend
well
immun
system
limit
impact
recent
chang
gut
lung
microbiom
composit
dysbiosi
also
relat
dysfunct
immun
modul
respiratori
immun
respons
complex
inborn
error
present
level
essenti
pathway
summar
follow
firstli
pathogen
detect
host
cell
identif
reli
set
pathogen
associ
molecular
profil
bind
pattern
recognit
receptor
prr
prr
found
transmembran
cytosol
extracellular
compon
among
prr
import
mention
tolllik
receptor
tlr
nucleotidebind
oligomer
domaincontain
nod
receptor
nodlik
receptor
nlr
rigilik
receptor
rlr
receptor
import
respiratori
infect
depend
prr
differ
intracellular
signal
pathway
activ
signal
pathway
converg
signal
hub
transcript
nuclear
factor
interferon
regulatori
factor
famili
mitogenactiv
protein
kinas
lead
induct
gene
express
encod
adhes
molecul
proinflammatori
cytokin
chemokin
type
interferon
among
other
nlr
directli
trigger
inflammasom
assembl
activ
lead
interleukin
il
process
type
iii
interferon
also
term
recent
identifi
regul
immun
homeostasi
respiratori
tract
infect
well
chronic
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
alveolar
macrophag
dendrit
cell
dc
import
role
sens
microb
thu
activ
lung
epitheli
cell
neutrophil
essenti
defens
bacteria
virus
aspergillu
well
pathogenesi
acut
lung
injuri
recent
studi
pattern
differenti
express
cellular
gene
share
sever
respiratori
pathogen
search
use
transcriptom
commonli
upregul
host
gene
relat
innat
immun
respons
andor
apoptosi
tolllik
rigilik
nlr
among
top
signal
gene
show
high
degre
interconnect
possibl
redund
respiratori
viral
bacteri
infect
adapt
immun
respons
requir
activ
antigenspecif
b
lymphocyt
trigger
protect
cellular
humor
respons
lymphocyt
subset
along
b
lymphocyt
dc
essenti
immun
defens
andor
regul
particular
protect
immun
tuberculosi
depend
lymphocyt
mainli
secret
interferongamma
tumor
necrosi
factor
alpha
lead
macrophag
activ
cytokin
product
bacteri
control
hivrev
tcell
lymphopenia
welldefin
risk
group
pneumocysti
jirovecii
pneumonia
pjp
also
situat
lymphocyt
count
lower
renal
transplant
recipi
studi
suscept
lower
respiratori
tract
infect
complex
requir
differ
approach
three
main
element
play
role
host
genet
background
relat
lung
tissu
function
immun
respons
pathogen
virul
determin
environment
factor
earli
life
children
year
age
challeng
period
pulmonari
tissu
immun
system
still
matur
process
continu
expos
airborn
antigen
howev
occurr
lifethreaten
bacterialviralfung
infect
otherwis
healthi
individu
deserv
immunolog
genet
studi
complic
upper
rti
includ
sinus
otiti
media
lower
airway
pneumonia
bronchiti
well
develop
bronchiectasi
interstiti
lung
diseas
organ
pneumonia
hyperreact
airway
diseas
inde
genet
suscept
concomit
ill
predispos
rti
also
play
role
includ
congenit
defect
airway
famili
congenit
bronchiectasi
tracheobronchomegali
regard
impair
mucociliari
clearanc
cystic
fibrosi
common
autosom
recess
disord
primari
caus
bronchiectasi
develop
world
mutat
welldefin
sever
influenc
gene
involv
inflammatori
antiinflammatori
mediat
disord
includ
ciliopathi
disord
humor
immun
alpha
circul
serin
proteas
inhibitor
serpin
made
liver
play
import
role
modul
immun
inflamm
apoptosi
possibl
cellular
senesc
program
defici
consid
genet
caus
copd
genet
factor
may
affect
diseas
activ
outcom
even
patient
without
defici
highthroughput
whole
genom
sequenc
technolog
novel
bioinformat
tool
reveal
sequenc
annot
complet
human
genom
well
genomewid
map
polymorph
microsatellit
marker
singl
nucleotid
polymorph
snp
order
character
genet
suscept
two
complementari
approach
envisag
whole
genom
associ
studi
wga
identif
variant
high
popul
frequenc
low
impact
individu
level
term
risk
infect
although
snp
identif
potenti
later
includ
healthcar
plan
protocol
mechanist
studi
identifi
diseasecaus
mutat
deleteri
effect
relat
high
risk
infect
individu
level
although
frequenc
gener
popul
low
mani
genet
variant
associ
complex
human
diseas
trait
often
confer
rel
small
increas
risk
accord
recent
review
primari
immunodefici
disord
pid
monogen
condit
mendelian
inherit
mainli
associ
crucial
defect
adapt
immun
innat
immun
respons
larg
redund
pleiotrop
natur
gene
product
thu
defect
potenti
counterbalanc
accord
literatur
anoth
view
suggest
patient
broad
immunodefici
may
present
one
mani
infect
phenotyp
particular
inborn
error
immun
narrow
suscept
one
specif
infect
set
inborn
error
affect
primarili
innat
immun
exercis
effect
adapt
immun
respons
rang
natur
infect
depend
sever
factor
improv
recognit
immun
dysregul
diseas
autoinflammatori
disord
interferonopathi
lead
chang
terminolog
annual
report
authorit
intern
union
immunolog
societi
categor
list
februari
inborn
error
immun
predomin
rti
phenotyp
includ
tabl
despit
limit
molecular
genet
studi
pulmonari
infect
sever
associ
describ
snp
bacteri
pneumonia
mycobacteri
infect
polymorph
affect
communityacquir
pneumonia
includ
among
other
relat
mannosebind
lectin
fc
gamma
receptor
ii
discuss
extens
elsewher
genet
contribut
propens
develop
sever
rsv
infect
estim
account
varianc
rsv
diseas
sever
sever
studi
attempt
link
candid
host
snp
diseas
sever
mostli
chemokin
receptor
prr
regard
tb
snp
frequent
found
loci
involv
correspond
receptor
genet
variat
dendrit
cellspecif
grab
nonintegrin
link
reduc
risk
develop
tb
mendelian
suscept
mycobacteri
diseas
syndrom
character
suscept
weakli
virul
mycobacteria
includ
attenu
vaccin
bacillu
calmetteguerin
bcg
strain
nontubercul
mycobacteria
ntm
differ
gene
mutat
identifi
relat
immun
use
exom
transcriptom
sequenc
three
rare
lossoffunct
variant
recent
character
gene
encod
rigilik
receptor
involv
sens
viral
rna
defici
caus
primari
immunodefici
manifest
extrem
suscept
common
respiratori
rna
virus
interestingli
human
primari
immunodefici
disord
pid
affect
b
cell
found
predispos
sever
influenza
howev
human
shown
essenti
protect
immun
primari
influenza
vivo
biolog
respons
modifi
brm
substanc
interact
modifi
host
immun
system
act
therapeut
target
consid
import
pathogen
categor
inborn
error
immunitybas
intern
union
immunolog
societi
annual
report
frontier
immunolog
wwwfrontiersinorg
process
diseas
monoclon
antibodi
mab
establish
therapi
malign
transplant
reject
sever
immun
disord
organ
system
even
infecti
diseas
safeti
problem
relat
immunomodul
infect
identifi
case
use
mab
indirectli
provid
insight
function
molecul
combat
particular
pathogen
increas
knowledg
immun
system
recent
consensu
document
review
group
drug
accord
target
site
action
expect
impact
suscept
infect
evid
risk
recommend
prevent
strategi
also
import
mention
influenc
previou
concomit
therapi
underli
condit
accumul
exposur
agent
regard
lower
rti
treatment
brm
result
increas
risk
report
pneumonia
influenzarel
complic
tb
ntm
pneumocysti
fungal
infect
histoplasmosi
take
account
impact
geograph
variat
incid
rate
knowledg
obtain
experi
prescript
brm
may
particularli
valuabl
understand
genet
inborn
error
type
infect
acquir
side
effect
may
help
identifi
genet
defect
favor
similar
infecti
phenotyp
current
knowledg
pleiotrop
effect
feasibl
show
biolog
agent
actual
mimic
inborn
error
immun
sever
parallel
infer
provid
tabl
contain
list
brm
accord
function
classif
inborn
error
categor
accord
common
infecti
phenotyp
tabl
data
present
extract
respect
consensu
document
list
main
rti
prevent
recommend
current
recommend
focus
rheumat
diseas
greater
experi
followup
time
year
number
patient
treat
biolog
therapi
target
cell
b
cell
variou
cytokin
includ
becom
essenti
treatment
rheumat
diseas
mainli
rheumatoid
arthriti
ra
ankylos
spondyl
psoriat
arthriti
well
immunemedi
diseas
moreov
addit
drug
novel
target
includ
inhibit
janu
activ
kinas
system
introduc
recent
immunomodul
offer
biolog
nonbiolog
diseasemodifi
therapi
prednison
contribut
greatli
increas
risk
opportunist
infect
oi
figur
present
site
action
associ
risk
frequent
prescrib
brm
two
recent
metaanalysi
calcul
rel
risk
infect
rheumat
patient
biolog
treatment
odd
ratio
absolut
increas
number
seriou
infect
per
patient
treatedyear
six
time
higher
observ
synthet
diseasemodifi
antirheumat
drug
dmard
differ
metaanalys
nation
registri
confirm
increas
impact
infect
seriou
infect
tb
associ
use
addit
risk
seriou
infect
highest
first
month
therapi
risk
although
year
risk
differ
convent
dmard
recurr
infect
ra
common
prospect
observ
cohort
studi
baselin
annual
rate
first
seriou
infect
addit
cohort
experienc
recurr
episodeyear
followup
highest
risk
within
first
year
respiratori
infect
common
episod
factor
shown
predict
infect
includ
age
function
statu
specif
comorbid
chronic
renallung
diseas
corticosteroid
treatment
number
previou
dmard
treatment
failur
previou
seriou
infect
current
treatment
inhibitor
nonbiolog
dmard
nevertheless
recent
data
suggest
patient
seriou
infect
expos
biolog
treatment
significantli
lower
risk
sepsi
fatal
outcom
patient
treat
convent
dmard
british
french
nation
biolog
registri
report
oi
rate
patient
use
therapi
particular
evid
increas
risk
tuberculosi
herp
zoster
listeria
infect
overal
incid
oi
significantli
differ
consid
drug
class
howev
rate
pjp
significantli
higher
patient
use
rituximab
comparison
therapi
absolut
risk
pjp
low
although
corticosteroid
exposur
strong
predictor
current
data
support
pjp
prophylaxi
rituximab
user
howev
may
appropri
certain
highrisk
individu
furthermor
rituximabassoci
neutropenia
impair
antibodi
respons
also
welldescrib
preclin
clinic
evid
indic
therapi
infliximab
adalimumab
golimumab
certolizumab
pegol
etanercept
associ
increas
risk
activ
tuberculosi
granulomat
condit
risk
seem
lower
etanercept
risk
also
depend
local
tb
preval
year
spanish
investig
report
estim
tb
incid
personyear
patient
ra
treat
infliximab
rate
higher
observ
rate
patient
rate
decreas
dramat
sinc
establish
latent
tuberculosi
infect
ltbi
screen
prior
biolog
therapi
essenti
rule
ltbi
individu
order
reduc
risk
activ
tb
reactiv
interferongamma
releas
assay
igra
use
tool
ltbi
diagnosi
specif
tuberculin
skin
test
tst
show
crossreact
bcgvaccin
ntm
sensit
moreov
invitro
assay
incorpor
mitogen
control
detect
presenc
anergi
common
patient
immunosuppress
therapi
howev
clinic
perform
igra
still
controversi
due
varieti
concomit
immunosuppress
drugregimen
use
time
ltbi
screen
popul
heterogen
sever
diseas
therefor
clinic
accuraci
igra
seem
differenti
affect
depend
specif
type
immun
disord
crohn
diseas
andor
concomit
drugprofil
azathioprin
highdos
corticosteroid
could
neg
affect
clinic
perform
igra
compar
immunemedi
diseas
psoriasi
inflammatori
rheumat
diseas
thu
seem
prudent
conveni
perform
dual
ltbi
test
tst
igra
patient
ra
underli
structur
lung
diseas
increas
risk
develop
ntm
infect
mostli
mycobacterium
avium
countri
ntm
infect
common
tb
treatment
howev
still
establish
recommend
regard
screen
prophylaxi
baselin
chest
xray
recommend
prior
start
therapi
patient
chronic
unexplain
cough
workup
includ
chest
comput
tomographi
scan
cultur
respiratori
specimen
immun
strategi
recommend
case
regardless
whether
patient
pid
receiv
immunosuppress
treatment
import
vaccin
accord
nation
immun
routin
schedul
patient
treatment
pneumococc
ageappropri
antivir
vaccin
ie
influenza
administ
immun
brm
wellestablish
regard
inactiv
vaccin
precaut
taken
live
vaccin
howev
even
respons
vaccin
impair
patient
pid
may
effect
patient
receiv
brm
may
partial
explain
concept
train
immunitybas
vaccin
conclus
rti
belong
common
caus
infect
human
worldwid
genet
contribut
sever
rti
may
mask
intervent
inborn
error
innat
immun
show
us
absenc
measur
immunolog
defect
exclud
immunodefici
function
genet
studi
necessari
order
fulli
valid
impact
host
genet
lung
infect
knowledg
obtain
experi
prescript
brm
may
particularli
valuabl
infect
acquir
side
effect
may
help
identifi
genet
defect
similar
infecti
phenotyp
meantim
recommend
base
biolog
rational
clinic
experi
mandatori
order
prevent
reemerg
sever
infect
cp
organ
structur
supervis
manuscript
elabor
revis
literatur
wrote
part
everi
chapter
al
revis
literatur
wrote
section
relat
immun
respons
infect
part
genet
edit
manuscript
il
rvh
jd
revis
wrote
aspect
relat
tuberculosi
jd
also
supervis
manuscript
elabor
lm
revis
wrote
section
regard
impact
biolog
respons
modifi
special
relat
rheumatolog
diseas
lm
al
rvh
prepar
figur
mm
cr
revis
aspect
relat
immunodefici
impact
brm
children
ib
revis
host
genet
factor
author
revis
approv
final
version
manuscript
research
support
two
grant
instituto
de
salud
carlo
iii
pi
pi
integr
plan
nacion
de
fund
jointli
isciii
gener
de
fondo
europeo
de
desarrollo
region
feder
jd
research
miguel
servet
programm
cp
award
programa
german
tria
sapien
catalunya
la
pedrera
